Blinatumomab biosimilar is a recombinant bispecific antibody targeting CD19 and CD3E, developed for research applications in immuno-oncology and T-cell engager studies. This research-grade antibody reproduces the mechanism of action of Blinatumomab by redirecting cytotoxic T cells toward CD19-expressing B cells.
Produced under strict quality control, this recombinant antibody is suitable for a wide range of immunotherapy, leukemia, and lymphoma research studies.
ProteoGenix provides high-quality research antibodies at competitive pricing, enabling laboratories to access reliable reagents for advanced immunology and oncology research.
Pricing and Availability
This Blinatumomab biosimilar antibody is available for research use with flexible purchasing options depending on quantity and project requirements.
Product Highlights
- Recombinant Blinatumomab biosimilar
- Targets CD19 and CD3E
- Bispecific T-cell engager antibody
- High purity research-grade material
- Competitive price for research laboratories
- Suitable for immuno-oncology studies
Applications
This antibody can be used in:
- Immuno-oncology research
- T-cell engager assays
- Cytotoxicity studies
- Flow cytometry experiments
- Functional immune assays
- Leukemia and lymphoma research
There are no reviews yet.